乐普医疗(300003) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥1,736,231,253.08, a decrease of 9.67% compared to ¥1,922,028,839.15 in the same period last year[4] - Net profit attributable to shareholders was ¥378,539,846.83, down 21.44% from ¥481,871,134.58 year-on-year[4] - Total operating revenue decreased to ¥1,736,231,253.08 from ¥1,922,028,839.15, representing a decline of approximately 9.66% year-over-year[27] - Net profit for the period was ¥377,214,013.29, down from ¥492,760,543.46, indicating a decrease of approximately 23.36%[28] - Operating profit decreased to ¥468,447,639.53 from ¥609,221,198.42, reflecting a decline of around 23.1%[28] - Basic earnings per share decreased to ¥0.2053 from ¥0.2594, a drop of approximately 20.9%[29] - The company reported a total comprehensive income of ¥389,042,851.43, down from ¥483,962,303.22, a decrease of approximately 19.6%[28] Cash Flow - The net cash flow from operating activities increased by 196.09% to ¥419,022,240.55, compared to ¥141,518,257.63 in the previous year[4] - Cash flow from operating activities increased significantly to ¥419,022,240.55 from ¥141,518,257.63, marking an increase of about 195.5%[29] - The net cash flow from investing activities was -464,047,420.78, compared to -280,016,903.64 in the previous period, indicating a significant increase in cash outflow for investments[30] - The total cash inflow from financing activities was 854,168,158.32, up from 646,677,567.42, reflecting a strong increase in financing received[30] - The net cash flow from financing activities was 82,162,782.14, a turnaround from -52,062,147.66 in the previous period, showing improved financial health[30] - The company reported a cash increase of 38,471,234.23, contrasting with a decrease of -188,896,639.47 in the previous period, suggesting a recovery in cash position[30] Assets and Liabilities - Total assets at the end of the reporting period were ¥25,233,363,806.46, reflecting a 2.69% increase from the previous year[4] - The company's total liabilities increased to CNY 8,074,135,866.99 from CNY 7,832,663,884.27, representing a rise of about 3.09%[25][26] - The total equity attributable to shareholders rose to CNY 15,615,828,015.50, up from CNY 15,201,421,378.82, indicating an increase of approximately 2.73%[26] - Cash and cash equivalents at the end of the period were CNY 3,729,685,667.04, slightly up from CNY 3,718,016,911.13, showing a marginal increase of 0.46%[24] - Accounts receivable increased significantly to CNY 1,857,183,008.74 from CNY 1,530,657,231.48, marking a growth of approximately 21.31%[24] - Inventory decreased to CNY 1,977,616,736.79 from CNY 2,030,235,942.18, reflecting a decline of about 2.59%[24] Shareholder Information - Total number of common shareholders at the end of the reporting period is 94,228[16] - The largest shareholder, China Shipbuilding Industry Group, holds 12.98% of shares, totaling 244,063,788 shares[16] - Shareholder Pu Zhongjie holds 12.13% of shares, totaling 228,074,749 shares, with 171,056,062 shares pledged[17] - WP Medical Technologies, Inc. holds 6.59% of shares, totaling 123,968,600 shares, with 92,976,450 shares pledged[17] - The top ten shareholders account for significant portions of the company's equity, with the largest holding being 12.98%[16] - The company has a total of 171,056,062 restricted shares held by Pu Zhongjie, which are subject to management lock-up[20] Investment and R&D - The company plans to continue focusing on research and development, with R&D expenses increasing to ¥203,326,022.08 from ¥197,385,261.91, an increase of about 3.5%[27] - The company's long-term investments in equity increased to CNY 1,212,784,329.49 from CNY 1,189,771,189.43, a growth of approximately 1.12%[24] Financial Expenses - Financial expenses rose to ¥33,282,300, a significant increase of 3,726.23% year-on-year, primarily due to foreign exchange losses[10] - Cash paid for debt repayment was 682,000,000.00, compared to 478,000,000.00 previously, indicating a higher commitment to servicing debt[30] - Cash paid for dividends and interest was 51,814,597.34, up from 38,686,008.93, reflecting an increase in shareholder returns[30]